Fusion Pharmaceuticals Taps James O’Leary as Chief Medical Officer

Fusion Pharmaceuticals has appointed James O’Leary as its chief medical officer. O’Leary’s experience includes roles at ImmunoGen (NASDAQ: [[ticker:IMGN]]), Idera Pharmaceuticals (NASDAQ: [[ticker:IDRA]]), Array Biopharma, and Deciphera (NASDAQ: [[ticker:DCPH]]), Takeda (NYSE: [[ticker:TAK]]), Bayer, and Pfizer (NYSE: [[ticker:PFE]]). Most recently O’Leary was a global project team leader for a late-stage asset directing global strategy and regulatory approvals at Takeda Pharmaceutical (NYSE: [[ticker:TAK]]).

Fusion, which has sites in Boston and Hamilton, Ontario, is developing new radiopharmaceuticals—drugs containing radioactive isotopes—to treat a range of cancer types. Lead program FPI-1434 is in Phase 1 testing, a study financed by a more than $100 million Series B financing Fusion completed in 2019.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine. View all posts by Sarah de Crescenzo